BCL2 and glioma: The pro-apoptotic member of the BCL2 family, BAX, showed a similarly low level of expression between low- and high-grade gliomas (p = 0.471); while there is an increase in the expression of the anti-apoptotic family member, BCL2, in low-grade gliomas (low-grade 50% vs. high-grade 32% gliomas; (p = 0.574) (Figure 2).